The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy

References

• Lee W. Hepatitis B virus infection. N Engl J Med 1997;337: 1733–1745.
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and controlmeasures. J Viral Hepat 2004;11:97–107.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507–539.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519–528.
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–7368.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097–5100.
   PubMed Web of Science ®Google Scholar
• Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:4769–4776.
   PubMed Web of Science ®Google Scholar
• Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011;90:1219–1223.
   PubMed Web of Science ®Google Scholar
• He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008;87:481–485.
   PubMed Web of Science ®Google Scholar
• Lim ST, Gao F, Quek R, et al. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007;79: 132–137.
   PubMed Web of Science ®Google Scholar
• Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74: 158–165.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006;91:554–557.
   PubMed Web of Science ®Google Scholar
• Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008;87:475–480.
   PubMed Web of Science ®Google Scholar
• Koo YX, Tan DS, Tao M, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010;116:115–121.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011;117:1792–1798.
   PubMed Web of Science ®Google Scholar
• Targhetta C, Cabras MG, Mamusa AM, et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008;93:951–952.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27: 605–611.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:2013–2017.
   PubMed Web of Science ®Google Scholar
• an der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257–225.
   PubMed Web of Science ®Google Scholar
• Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000.
   PubMed Web of Science ®Google Scholar
• Lazdina U, Alheim M, Nyström J, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003;84:139–146.
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118–1129.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Oketani M, Ido A, Uto H, et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012;42:627–636.
   PubMed Web of Science ®Google Scholar
• Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469–475.
   PubMed Web of Science ®Google Scholar
• Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood 2008;22:117–126.
   Web of Science ®Google Scholar
• Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 2008;6:569–579.
   PubMed Web of Science ®Google Scholar